Copley launches world’s first dissolution tester for inhaled drugs
Copley Scientific claims new dissolution testing apparatus is first commercially available device specifically designed for inhaled drug formulations.
The technology, launched on Monday, determines the dissolution of size-fractionated particles using methodologies similar to those employed during the analysis of drug release from transdermal patches.
The UK firm explained that unlike for oral dosage form where use of dissolution testing is already well established it “is not yet in widespread use for inhaled products, where the prime focus is successful deposition in the lung.”
Copley added that, while there are no official tests for inhaled drugs, greater use of dissolution analysis could help formulators deliver larger, more complex active pharmaceutical ingredients (APIs) with improved release profiles.
